Pluto Bioinformatics

GSE102534: Comparative gene expression profiling of MHH-CALL4 cells subject to pharmacological JAK2 inhibitor treatment (ruxolitinib or CHZ868) or shRNA-mediated JAK2 depletion in vitro

Bulk RNA sequencing

Gene expression profiling was performed to characterise transcriptional programs associated with response to type I JAK2 inhibitor ruxolitinib, type II JAK2 inhibitor CHZ868 or shRNA-mediated JAK2 knockdown in MHH-CALL4 cells. SOURCE: SANGKYU KIM (sang-kyu.kim@petermac.org) - GENE REGULATION PETER MACCALLUM CANCER CENTRE